ArticleCancer research communications2025
Impact of Staging, Histologic Grading, and Racial Background on Lip Cancer Survival in the United States: Insights from the SEER Database (2010-2020).
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lip cancer has a distinct biological behavior within head and neck oncology, although population-based survival studies remain scarce. We analyzed data from the United States Surveillance, Epidemiology, and End Results (SEER) program to assess the prognostic value of tumor stage, histologic grade, and race in lip cancer diagnosed during 2010 to 2020. A retrospective cohort of 6,717 invasive lip tumors was extracted from 17 SEER registries. Cause-specific survival was estimated using Kaplan-Meier curves and compared with log-rank tests. Cox proportional hazards regression generated HRs with 95% confidence intervals. Among 4,273 lip cancer cases with SEER staging, survival varied significantly by disease extent. Localized tumors had a 94% lower risk of cancer-specific death compared with distant/regional metastasis, with median survival times of 97 and 18 months, respectively. Histologic grade correlated with survival in univariate but not multivariate analysis (after adjusting for stage and race). White and Asian/Pacific Islander patients had better survival, whereas American Indian/Alaska Native patients (0.4% of the cohort) showed a significantly elevated risk, warranting further study in this underrepresented group. In this national cohort, disease stage at diagnosis and race were key survival determinants in lip cancer. Localized tumors reduced mortality by 94% versus distant disease. Histologic grade added no further prognostic value after accounting for stage and race, underscoring the need for longer follow-up and better registry data. SIGNIFICANCE: This SEER-based study provides the first lip-specific survival curves, revealing localized disease reduces mortality by 94% versus distant metastasis. Race (American Indian/Alaska Native patients faced triple the mortality risk) outweighed histologic grade in prognosis. Limited tumor-node-metastasis data highlighted registry gaps, whereas nodal sampling trends supported early regional assessment. Findings refine risk stratification, expose disparities needing targeted interventions, and set benchmarks for future research in this uncommon but clinically significant cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.